苏州朗科生物技术有限公司

Longcure is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of RNA interference (RNAi) therapeutics. The company utilizes its proprietary siRNA delivery platforms, including GalNAc conjugation technology, to target chronic diseases with high unmet medical needs. Its lead candidate, LC001, is a small interfering RNA (siRNA) designed to treat chronic Hepatitis B by silencing viral gene expression to achieve a functional cure. Longcure's research and development efforts are primarily focused on liver-targeted therapies for infectious diseases and metabolic disorders. The company was founded by Dr. Li Longcheng, a recognized expert in the field of RNA-based medicine.